Life Sciences Session #4 -How to optimise your regulatory exclusivity rights for pharmaceutical products?

 

Please join us on 25 May 2021 from 13:30 to 14:30 for our fourth online Life Sciences Session focusing on regulatory exclusivity rights for pharmaceutical products, which will include data exclusivity, orphan exclusivity, SPCs and paediatric rewards.

The COVID-19 pandemic challenges companies and firms worldwide, and requires us all to adopt new proactive approaches. While COVID-19 prevents us from being together, our Life Sciences team is taking the initiative to offer you short, digestible and regular online Life Sciences Sessions.

In our upcoming fourth session, our experts, Kirian Claeyé  and Laura Traest, will navigate the maze of regulatory exclusivity rights, update you on a number of significant recent developments, and discuss what is still to come. Specific topics will include:

  • The SPC manufacturing waiver
  • The CJEU’s latest case-law on SPC rights: Santen and Royalty Pharma
  • The European Commission’s review of Orphan Exclusivity and Paediatric Extensions
  • The General Court’s very recent Polpharma ruling on Data Exclusivity

This webinar will be in English and has been accredited with 1 point by the IBJ/IJE.

We hope to virtually meet you soon,


The ALTIUS IP Team

 

OUR SPEAKERS

 

Voir aussi : ALTIUS

Calendrier

Webinaires & Formations & Evénements

29 Jun
logo - company

Alles heeft een prijs. Do’s en don’ts inzake (rechtsgeldige) prijsherzieningen en...

Het hanteren van marktconforme prijzen is van doorslaggevend belang bij het (kunnen) leveren van producten en diensten....

More info

LexGO Network